Initial estimates of the minimal clinically important difference for the Neuropathic Pain Symptom Inventory: a systematic meta-analysis.
This study estimates the Minimal Clinically Important Difference for the Neuropathic Pain Symptom Inventory to be around 6.21 to 8.71, depending on the method used.
Where it sits
this study against the rest of the cibinetide corpusSummary and findings
The study aimed to calculate a Minimal Clinically Important Difference (MCID) for the Neuropathic Pain Symptom Inventory (NPSI) based on a systematic review and meta-analysis of neuropathic pain trials. A total of 12 trials with 17 treatment arms were included. The calculated MCID estimates ranged from 6.21 to 8.71 depending on the method used.
Abstract
<h4>Background</h4>The Neuropathic Pain Symptom Inventory (NPSI) is a commonly used assessment in neuropathic pain (NP) trials, yet a Minimal Clinically Important Difference (MCID) has not been established. An MCID would enhance the interpretability of NPSI scores, guiding clinicians and researchers in assessing clinically important improvements in NP symptoms. The aim of this study was to calculate an MCID from the available scientific research that used the NPSI.<h4>Methods</h4>We conducted a systematic review and meta-analysis of NP trials reporting the NPSI. Four distributional approaches were applied to estimate the MCID: 1) meta-regression on the set of standard deviation (SD) of change scores, 2) meta-regression on the set of baseline SD scores, 3) simple aggregation on the set of SD of change scores, and 4) simple aggregation on the set of baseline SD scores. Only treatment arms within Randomized Controlled Trials (RCTs) were examined for MCID estimation. Control arms were examined separately in a sensitivity analysis using the simple aggregation method for both SD of change and baseline SD sets. Bias for each included study was assessed using the Cochrane tool for quality assessment of randomized controlled trials.<h4>Results</h4>323 trials were examined, 12 were selected for inclusion with a total of 17 treatment arms. The calculated MCID estimates for the NPSI total score (range 1-100) were 6.21 for the SD of change meta-regression and 7.1 for baseline SD meta regression. The MCID values aggregated using simple aggregation methods were 7.95 using pooled SD of change scores, 7.8 using pooled baseline SD. Control arms had a MCID of 8.04 for SD of Change and 8.71 for Baseline SD.<h4>Conclusion</h4>This study provides preliminary MCID estimates for the NPSI. Limitations include limited data for NP subtypes, highlighting the need for additional anchor-based and etiology-specific MCID research to refine these estimates. These findings can aid in future NP trial design and the interpretation of results.<h4>Systematic review registration</h4>https://www.crd.york.ac.uk/PROSPERO/view/CRD42025649343, PROSEPRO CRD42025649343.
Background
The Neuropathic Pain Symptom Inventory (NPSI) is widely utilized in assessing neuropathic pain (NP) symptoms, yet a Minimal Clinically Important Difference (MCID) has not been established, which is crucial for interpreting clinical significance. Previous studies have not provided a consensus on what constitutes a clinically meaningful change in NPSI scores. This study addresses this gap by calculating an MCID based on existing trials, which is important for guiding clinicians and researchers in evaluating treatment effects.
Methods
The study conducted a systematic review and meta-analysis of NP trials that reported NPSI scores, focusing on treatment arms within Randomized Controlled Trials (RCTs). A total of 323 trials were examined, and 12 were selected for inclusion, resulting in 17 treatment arms. Four distributional approaches were used to estimate the MCID: meta-regression on change scores, meta-regression on baseline scores, and simple aggregation methods for both change and baseline scores.
Results
The primary endpoint for the MCID estimate was 6.21 for the SD of change meta-regression. Additional estimates included 7.1 for baseline SD meta-regression, 7.95 for pooled SD of change scores, and 7.8 for pooled baseline SD. Control arms showed MCID values of 8.04 for SD of change and 8.71 for baseline SD.
Interpretation
These MCID estimates provide a preliminary framework for understanding clinically significant changes in NPSI scores. While the findings are statistically significant, the clinical relevance of these effect sizes may vary, and the study's limitations, such as the small number of included trials and potential biases, should be considered. This research may inform future NP trial designs and the interpretation of results, but further studies are needed to validate these findings.
Key findings
- MCID estimate for NPSI total score was 6.21 for SD of change meta-regression.
- MCID estimate for NPSI total score was 7.1 for baseline SD meta-regression.
- MCID using pooled SD of change scores was 7.95.
- MCID using pooled baseline SD was 7.8.
- Control arms had a MCID of 8.04 for SD of change.
- Control arms had a MCID of 8.71 for baseline SD.
Limitations
- Only 12 trials included in the analysis.
- Limited data for neuropathic pain subtypes.
- Potential biases in included studies.
- Focus solely on treatment arms of RCTs.